Amphastar Pharmaceuticals Inc vs State Street Real Estate Select Sector SPDR ETF — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.04 (market cap $868.62M), while State Street Real Estate Select Sector SPDR ETF trades at $44.57. The key difference: State Street Real Estate Select Sector SPDR ETF is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | XLRE | |
|---|---|---|
Market Cap | $868.62M | — |
Sector | Health | Sector/Thematic |
52-Week High | $30.81 | $46.01 |
52-Week Low | $16.87 | $40.01 |
Enterprise Value | $1.27B | — |
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $19.86, down 2.22% today, with a bullish technical signal from moving averages. The company reported mixed Q2 2026 results, beating EPS estimates with $0.91 versus $0.62 expected, but revenue growth remains modest. Valuation ratios appear reasonable with P/E of 12.08 and P/S of 1.3, while profitability metrics show a net income margin of 10.76% and ROE of 10.3%.
Outlook is cautious due to recent earnings misses and regulatory scrutiny, including an FDA warning letter. Analyst consensus leans Hold (66.67%) with limited Buy support. Key risks include competitive pressures and potential tariff impacts on generic drugs. Cash flow trends improved in 2026 with net cash flow rising to $36 million.
XLRE trades at $44.47 with minimal daily movement (+0.16%), while technical indicators signal a bearish trend with selling pressure outweighing buying signals. The ETF's low expense ratio of 0.08% and focus on U.S. real estate investment trusts provide cost-efficient exposure to the sector, which has shown resilience amid inflation pressures and interest rate volatility in 2026.
The outlook for XLRE hinges on real estate sector recovery, with REITs demonstrating strong fundamentals despite macroeconomic headwinds. Key risks include interest rate sensitivity and inflation persistence, while opportunities lie in the sector's attractive valuations and potential for dividend growth as the Fed's rate policy evolves.
Trailing returns across standard periods
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →XLRE tracks the Real Estate Select Sector Index, providing exposure to S&P 500 real estate companies. It focuses on equity REITs across residential, industrial, and healthcare sub-sectors, with top holdings like Welltower, Prologis, and American Tower.
Read more on XLRE →